Technology | October 22, 2009

FlowCardia Expands Options for Patients With Chronic Total Occlusions

October 22, 2009 – FlowCardia Inc. yesterday began its U.S. launch of the over the wire (OTW) delivery platform for the CROSSER 14S and CROSSER 14P peripheral chronic total occlusions (CTOs) recanalization catheters. The Over the Wire CROSSER Catheter delivery platform provides interventional cardiologists, vascular surgeons, and interventional radiologists with an endovascular tool to treat even the most distal and complex peripheral occlusions. CROSSER OTW catheters facilitate guide wire exchanges using peripheral interventionalists' preferred delivery platform, thus providing various levels of catheter support, pushability, and steerability during percutaneous treatment in patients suffering from blocked arteries in the legs. "The new Over the Wire CROSSER Catheter allows me to freely exchange my guide wire, giving me the steerability and support necessary to tackle the toughest of CTOs with ease," said David Allie, M.D., a cardiothoracic surgeon at the Medical Center of Acadiana in Lafayette, La. "When faced with CTOs, I use CROSSER as my frontline therapy to stay in the central lumen, giving me the freedom to choose the best subsequent treatment option for patients suffering from completely blocked arteries." The CROSSER Catheter is a minimally-invasive endovascular device that utilizes high-frequency, mechanical vibration to facilitate passage through blockages in the peripheral and coronary arteries. It is designed as a frontline therapy to enable central lumen crossing of chronically occluded arteries thereby maximizing physicians' therapeutic options. More than 7,500 CROSSER Catheter procedures have been performed to date by physicians around the world. For more information: www.flowcardia.com

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init